Infectious Disease Diagnostics Market by Product & Service, Test Type, Sample, Technology, Disease, End User - Global Forecast to 2030

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 MARKET SCOPE
  • 1.3.1 MARKETS COVERED & REGIONAL SCOPE
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 KEY STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
• 2.2 RESEARCH APPROACH
  • 2.2.1 SECONDARY DATA
    • 2.2.1.1 Key secondary sources
    • 2.2.1.2 Key data from secondary sources
  • 2.2.2 PRIMARY DATA
    • 2.2.2.1 Primary sources
    • 2.2.2.2 Key data from primary sources
    • 2.2.2.3 Key industry insights
    • 2.2.2.4 Breakdown of primary interviews
• 2.3 MARKET SIZE ESTIMATION
  • 2.3.1 BOTTOM-UP APPROACH
    • 2.3.1.1 Approach 1: Company revenue estimation approach
    • 2.3.1.2 Approach 2: Presentations of companies and primary interviews
    • 2.3.1.3 Growth forecast
    • 2.3.1.4 CAGR projections
  • 2.3.2 TOP-DOWN APPROACH
• 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
• 2.5 MARKET SHARE ASSESSMENT
• 2.6 RESEARCH ASSUMPTIONS
  • 2.6.1 PARAMETRIC ASSUMPTIONS
• 2.7 RESEARCH LIMITATIONS
• 2.8 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 INFECTIOUS DISEASE DIAGNOSTICS MARKET OVERVIEW
• 4.2 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2025 VS. 2030 (USD MILLION)
• 4.3 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2025 VS. 2030 (USD MILLION)
• 4.4 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2025 VS. 2030 (USD MILLION)
• 4.5 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2025 VS. 2030 (USD MILLION)
• 4.6 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2025 VS. 2030 (USD MILLION)
• 4.7 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2025 VS. 2030 (USD MILLION)
• 4.8 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
• 4.9 INFECTIOUS DISEASE DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Rising prevalence of infectious diseases
    • 5.2.1.2 Rising focus on R&D and funding investments for infectious disease diagnostic products
    • 5.2.1.3 Adoption of innovative & advanced technologies for infectious disease diagnosis
    • 5.2.1.4 Gradual shift from centralized laboratories to decentralized PoC testing centers
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Unfavorable reimbursements
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 High growth potential of emerging economies
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Stringent regulatory guidelines for IVD products
    • 5.2.4.2 Operational barriers and shortage of skilled laboratory technicians
• 5.3 PRICING ANALYSIS
  • 5.3.1 INDICATIVE SELLING PRICE TREND OF INFECTIOUS DISEASE DIAGNOSTICS PRODUCTS, 2023-2025
  • 5.3.2 INDICATIVE SELLING PRICE TREND OF INFECTIOUS DISEASE TEST KITS & ASSAYS, BY KEY PLAYER,2023-2025
  • 5.3.3 INDICATIVE SELLING PRICE TREND OF INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS, BY REGION, 2023-2025
• 5.4 PATENT ANALYSIS
  • 5.4.1 LIST OF MAJOR PATENTS
• 5.5 VALUE CHAIN ANALYSIS
• 5.6 SUPPLY CHAIN ANALYSIS
• 5.7 TRADE ANALYSIS
  • 5.7.1 TRADE ANALYSIS FOR DIAGNOSTIC & LABORATORY REAGENTS
  • 5.7.2 IMPORT DATA (HS CODE 3822)
  • 5.7.3 EXPORT DATA (HS CODE 3822)
• 5.8 ECOSYSTEM ANALYSIS
  • 5.8.1 INFECTIOUS DISEASE DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM
• 5.9 PORTER'S FIVE FORCES ANALYSIS
  • 5.9.1 THREAT OF NEW ENTRANTS
  • 5.9.2 THREAT OF SUBSTITUTES
  • 5.9.3 BARGAINING POWER OF BUYERS
  • 5.9.4 BARGAINING POWER OF SUPPLIERS
  • 5.9.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.10 REGULATORY LANDSCAPE
  • 5.10.1 REGULATORY FRAMEWORK
    • 5.10.1.1 North America
      • 5.10.1.1.1 US
      • 5.10.1.1.2 Canada
    • 5.10.1.2 Europe
      • 5.10.1.2.1 Germany
      • 5.10.1.2.2 UK
      • 5.10.1.2.3 France
      • 5.10.1.2.4 Italy
    • 5.10.1.3 Asia Pacific
      • 5.10.1.3.1 China
      • 5.10.1.3.2 Japan
      • 5.10.1.3.3 India
    • 5.10.1.4 Latin America
      • 5.10.1.4.1 Brazil
      • 5.10.1.4.2 Mexico
    • 5.10.1.5 Middle East
      • 5.10.1.5.1 Africa
  • 5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.11 TECHNOLOGY ANALYSIS
  • 5.11.1 KEY TECHNOLOGIES
    • 5.11.1.1 Immunodiagnostics
  • 5.11.2 COMPLEMENTARY TECHNOLOGIES
    • 5.11.2.1 Polymerase Chain Reaction (PCR)
  • 5.11.3 ADJACENT TECHNOLOGIES
    • 5.11.3.1 Next-generation Sequencing (NGS)
• 5.12 KEY CONFERENCES & EVENTS, 2025-2026
• 5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.14 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.14.2 BUYING CRITERIA
• 5.15 INVESTMENT & FUNDING SCENARIO
• 5.16 CASE STUDY ANALYSIS
  • 5.16.1 CASE STUDY 1: IMPLEMENTING RAPID PCR TESTING TO IMPROVE NOROVIRUS DIAGNOSIS & BED MANAGEMENT
  • 5.16.2 CASE STUDY 2: USING MOLECULAR DIAGNOSTICS TO IDENTIFY ATYPICAL RESPIRATORY INFECTIONS
  • 5.16.3 CASE STUDY 3: RAPID DIFFERENTIATION OF VIRAL & BACTERIAL INFECTION IN PEDIATRIC PATIENTS
• 5.17 IMPACT OF AI/GENERATIVE AI ON INFECTIOUS DISEASE DIAGNOSTICS MARKET
  • 5.17.1 INTRODUCTION
  • 5.17.2 MARKET POTENTIAL OF AI
  • 5.17.3 AI-USE CASES
  • 5.17.4 IMPLEMENTATION OF AI, BY KEY COMPANY & CASE
  • 5.17.5 FUTURE OF AI IN INFECTIOUS DISEASE DIAGNOSTICS MARKET
• 5.18 TRUMP TARIFF IMPACT ON INFECTIOUS DISEASE DIAGNOSTICS MARKET
  • 5.18.1 INTRODUCTION
  • 5.18.2 KEY TARIFF RATES
  • 5.18.3 PRICE IMPACT ANALYSIS
  • 5.18.4 KEY IMPACT ON COUNTRY/REGION
    • 5.18.4.1 North America
    • 5.18.4.2 Europe
    • 5.18.4.3 Asia Pacific
  • 5.18.5 IMPACT ON END-USE INDUSTRIES
    • 5.18.5.1 Diagnostic laboratories
    • 5.18.5.2 Hospitals & clinics
    • 5.18.5.3 Academic research institutes

6 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE

• 6.1 INTRODUCTION
• 6.2 REAGENTS, KITS, AND CONSUMABLES
  • 6.2.1 RECURRENT PURCHASE TO PROPEL MARKET
• 6.3 INSTRUMENTS
  • 6.3.1 RAPID TECHNOLOGICAL ADVANCEMENTS FOR ADVANCED ACCURACY TO DRIVE MARKET
• 6.4 SOFTWARE & SERVICES
  • 6.4.1 INCREASING FOCUS ON VALUE-ADDED SERVICES TO SUPPORT MARKET GROWTH

7 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING

• 7.1 INTRODUCTION
• 7.2 LABORATORY TESTING
  • 7.2.1 HIGHER SENSITIVITY & SPECIFICITY TO FUEL UPTAKE
• 7.3 POC TESTING
  • 7.3.1 RAPID TURNAROUND TIME AND INCREASING CLIA APPROVALS FOR POC TESTS TO PROPEL MARKET

8 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE

• 8.1 INTRODUCTION
• 8.2 BLOOD, SERUM, AND PLASMA
  • 8.2.1 HIGHER VERSATILITY, ENHANCED CLINICAL EFFICACY, AND IMPROVED REIMBURSEMENT POLICIES TO DRIVE MARKET
• 8.3 URINE
  • 8.3.1 NON-INVASIVE NATURE AND ENHANCED PATIENT CONVENIENCE TO BOOST DEMAND
• 8.4 OTHER SAMPLE TYPES

9 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE

• 9.1 INTRODUCTION
• 9.2 HEPATITIS
  • 9.2.1 HEPATITIS B
    • 9.2.1.1 Highly contagious infection and requirement for regular monitoring to fuel market
  • 9.2.2 HEPATITIS C
    • 9.2.2.1 Rising incidence of chronic HCV and supportive government initiatives to drive market
  • 9.2.3 OTHER HEPATITIS DISEASES
• 9.3 HIV
  • 9.3.1 INCREASING PREVALENCE OF AIDS TO BOOST DEMAND
• 9.4 HOSPITAL-ACQUIRED INFECTIONS
  • 9.4.1 RISING BURDEN OF MRSA INFECTIONS TO FUEL MARKET
• 9.5 MOSQUITO-BORNE DISEASES
  • 9.5.1 RISING INCIDENCE OF DENGUE & MALARIA TO PROPEL MARKET
• 9.6 HPV
  • 9.6.1 RAPID TECHNOLOGICAL ADVANCES TO BOOST DEMAND
• 9.7 CHLAMYDIA TRACHOMATIS
  • 9.7.1 INCREASING AWARENESS INITIATIVES TO SUPPORT MARKET UPTAKE
• 9.8 NEISSERIA GONORRHEA
  • 9.8.1 RISING INCIDENCE OF GONORRHEA TO FUEL MARKET
• 9.9 TUBERCULOSIS
  • 9.9.1 INCREASING BURDEN OF TB IN UNDERSERVED AREAS TO DRIVE MARKET
• 9.10 INFLUENZA
  • 9.10.1 INCREASING FOCUS ON RAPID DIAGNOSIS USING POC TESTING METHODS TO FUEL MARKET
• 9.11 SYPHILIS
  • 9.11.1 IMPROVED SCREENING TECHNOLOGIES TO SUPPORT MARKET UPTAKE
• 9.12 OTHER INFECTIOUS DISEASES

10 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY

• 10.1 INTRODUCTION
• 10.2 IMMUNODIAGNOSTICS
  • 10.2.1 RISING PREVALENCE OF INFECTIOUS DISEASES AND DEMAND FOR RAPID DIAGNOSTIC KITS TO DRIVE MARKET
• 10.3 CLINICAL MICROBIOLOGY
  • 10.3.1 RAPID TURNAROUND TIME WITH HIGHER SENSITIVITY & RELIABLE RESULTS TO BOOST DEMAND
• 10.4 POLYMERASE CHAIN REACTION
  • 10.4.1 CONVENIENCE & COST-EFFECTIVENESS TO FUEL UPTAKE
• 10.5 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY
  • 10.5.1 ENHANCED SUITABILITY FOR POC TESTING WITH LOW-COST FEATURES TO FUEL UPTAKE
• 10.6 DNA SEQUENCING & NEXT-GENERATION SEQUENCING
  • 10.6.1 ADVANCEMENTS IN SEQUENCING TECHNOLOGIES AND RISING FOCUS ON MOLECULAR TARGETED DRUGS TO PROPEL MARKET
• 10.7 DNA MICROARRAY
  • 10.7.1 HIGH INSTRUMENT COSTS TO LIMIT MARKET
• 10.8 OTHER TECHNOLOGIES

11 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION

• 11.1 INTRODUCTION
• 11.2 DIAGNOSTICS
  • 11.2.1 INCREASING CLINICAL NEED FOR CONFIRMATORY TESTING & TIMELY TREATMENT TO DRIVE MARKET
• 11.3 SCREENING
  • 11.3.1 GROWING IMPORTANCE OF EARLY DISEASE DETECTION TO FUEL MARKET

12 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER

• 12.1 INTRODUCTION
• 12.2 DIAGNOSTIC LABORATORIES
  • 12.2.1 ABILITY TO CATER TO HIGH-END SPECIALTY TESTING TO PROPEL MARKET
• 12.3 HOSPITALS & CLINICS
  • 12.3.1 IMPROVED REIMBURSEMENTS AND CAPABILITY OF PURCHASING ADVANCED EQUIPMENT TO DRIVE MARKET
• 12.4 ACADEMIC RESEARCH INSTITUTES
  • 12.4.1 INCREASING R&D FUNDING INVESTMENTS TO FUEL MARKET
• 12.5 OTHER END USERS

13 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION

• 13.1 INTRODUCTION
• 13.2 NORTH AMERICA
  • 13.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK
  • 13.2.2 US
    • 13.2.2.1 High healthcare expenditure to drive market
  • 13.2.3 CANADA
    • 13.2.3.1 Supportive government initiatives for infectious disease prevention to fuel market
• 13.3 EUROPE
  • 13.3.1 EUROPE: MACROECONOMIC OUTLOOK
  • 13.3.2 GERMANY
    • 13.3.2.1 High adoption of advanced technologies to propel market
  • 13.3.3 UK
    • 13.3.3.1 Increasing number of diagnostic centers to fuel uptake
  • 13.3.4 FRANCE
    • 13.3.4.1 Rising expenditure on life sciences R&D to drive market
  • 13.3.5 ITALY
    • 13.3.5.1 Rising incidence of chronic diseases to boost demand
  • 13.3.6 SPAIN
    • 13.3.6.1 High prevalence of HIV and consolidation of diagnostic laboratories to drive market
  • 13.3.7 REST OF EUROPE
• 13.4 ASIA PACIFIC
  • 13.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK
  • 13.4.2 CHINA
    • 13.4.2.1 Increasing burden of hepatitis B virus cases and growing government focus on health surveillance to drive market
  • 13.4.3 JAPAN
    • 13.4.3.1 Presence of established healthcare system and universal reimbursement policies to fuel uptake
  • 13.4.4 INDIA
    • 13.4.4.1 High prevalence of TB & HIV to propel market
  • 13.4.5 REST OF ASIA PACIFIC
• 13.5 LATIN AMERICA
  • 13.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK
  • 13.5.2 BRAZIL
    • 13.5.2.1 Rising focus on initiating public-private investments for healthcare improvement to fuel uptake
  • 13.5.3 MEXICO
    • 13.5.3.1 Improving accessibility & affordability of healthcare services to support market growth
  • 13.5.4 REST OF LATIN AMERICA
• 13.6 MIDDLE EAST & AFRICA
  • 13.6.1 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK
  • 13.6.2 KINGDOM OF SAUDI ARABIA (KSA)
    • 13.6.2.1 Integration of digital health systems and improvements in healthcare infrastructure to fuel market
  • 13.6.3 UNITED ARAB EMIRATES (UAE)
    • 13.6.3.1 Rising requirement of high-quality healthcare services to support market growth
  • 13.6.4 REST OF MIDDLE EAST & AFRICA

14 COMPETITIVE LANDSCAPE

• 14.1 INTRODUCTION
• 14.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 14.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN INFECTIOUS DISEASE DIAGNOSTICS MARKET
• 14.3 REVENUE SHARE ANALYSIS, 2022-2024
• 14.4 MARKET SHARE ANALYSIS, 2024
• 14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 14.5.1 STARS
  • 14.5.2 EMERGING LEADERS
  • 14.5.3 PERVASIVE PLAYERS
  • 14.5.4 PARTICIPANTS
  • 14.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 14.5.5.1 Company footprint
    • 14.5.5.2 Region footprint
    • 14.5.5.3 Product & Service footprint
    • 14.5.5.4 Type of testing footprint
    • 14.5.5.5 Sample type footprint
• 14.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 14.6.1 PROGRESSIVE COMPANIES
  • 14.6.2 RESPONSIVE COMPANIES
  • 14.6.3 DYNAMIC COMPANIES
  • 14.6.4 STARTING BLOCKS
  • 14.6.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
    • 14.6.5.1 Detailed list of key startups/SMEs
    • 14.6.5.2 Competitive benchmarking of startups/SMEs (1/2)
    • 14.6.5.3 Competitive benchmarking of startups/SMEs (2/2)
• 14.7 COMPANY VALUATION & FINANCIAL METRICS
  • 14.7.1 FINANCIAL METRICS
  • 14.7.2 COMPANY VALUATION
• 14.8 BRAND/PRODUCT COMPARISON
  • 14.8.1 BRAND/PRODUCT COMPARATIVE ANALYSIS
• 14.9 COMPETITIVE SCENARIO
  • 14.9.1 PRODUCT/SERVICES LAUNCHES & APPROVALS
  • 14.9.2 DEALS
  • 14.9.3 EXPANSIONS

15 COMPANY PROFILES

• 15.1 KEY PLAYERS
  • 15.1.1 F. HOFFMANN-LA ROCHE LTD.
    • 15.1.1.1 Business overview
    • 15.1.1.2 Products/Services offered
    • 15.1.1.3 Recent developments
      • 15.1.1.3.1 Product/Service launches & approvals
      • 15.1.1.3.2 Deals
      • 15.1.1.3.3 Expansions
    • 15.1.1.4 MnM view
      • 15.1.1.4.1 Key strengths
      • 15.1.1.4.2 Strategic choices
      • 15.1.1.4.3 Weaknesses & competitive threats
  • 15.1.2 ABBOTT
    • 15.1.2.1 Business overview
    • 15.1.2.2 Products/Services offered
    • 15.1.2.3 Recent developments
      • 15.1.2.3.1 Product/Service launches & approvals
      • 15.1.2.3.2 Deals
    • 15.1.2.4 MnM view
      • 15.1.2.4.1 Key strengths
      • 15.1.2.4.2 Strategic choices
      • 15.1.2.4.3 Weaknesses & competitive threats
  • 15.1.3 DANAHER CORPORATION
    • 15.1.3.1 Business overview
    • 15.1.3.2 Products/Services offered
    • 15.1.3.3 Recent developments
      • 15.1.3.3.1 Product/Service launches & approvals
      • 15.1.3.3.2 Deals
      • 15.1.3.3.3 Expansions
    • 15.1.3.4 MnM view
      • 15.1.3.4.1 Key strengths
      • 15.1.3.4.2 Strategic choices
      • 15.1.3.4.3 Weaknesses & competitive threats
  • 15.1.4 BIOMERIEUX
    • 15.1.4.1 Business overview
    • 15.1.4.2 Products/Services offered
    • 15.1.4.3 Recent developments
      • 15.1.4.3.1 Product/Service launches & approvals
      • 15.1.4.3.2 Deals
    • 15.1.4.4 MnM view
      • 15.1.4.4.1 Key strengths
      • 15.1.4.4.2 Strategic choices
      • 15.1.4.4.3 Weaknesses & competitive threats
  • 15.1.5 THERMO FISHER SCIENTIFIC INC.
    • 15.1.5.1 Business overview
    • 15.1.5.2 Products/Services offered
    • 15.1.5.3 Recent developments
      • 15.1.5.3.1 Product/Service launches & approvals
      • 15.1.5.3.2 Deals
    • 15.1.5.4 MnM view
      • 15.1.5.4.1 Key strengths
      • 15.1.5.4.2 Strategic choices
      • 15.1.5.4.3 Weaknesses & competitive threats
  • 15.1.6 SIEMENS HEALTHINEERS AG
    • 15.1.6.1 Business overview
    • 15.1.6.2 Products/Services offered
    • 15.1.6.3 Recent developments
      • 15.1.6.3.1 Product/Service launches & approvals
      • 15.1.6.3.2 Deals
      • 15.1.6.3.3 Expansions
  • 15.1.7 HOLOGIC, INC.
    • 15.1.7.1 Business overview
    • 15.1.7.2 Products/Services offered
    • 15.1.7.3 Recent developments
      • 15.1.7.3.1 Product/Service launches & approvals
      • 15.1.7.3.2 Deals
  • 15.1.8 BECTON, DICKINSON AND COMPANY (BD)
    • 15.1.8.1 Business overview
    • 15.1.8.2 Products/Services offered
    • 15.1.8.3 Recent developments
      • 15.1.8.3.1 Product/Service launches & approvals
      • 15.1.8.3.2 Deals
      • 15.1.8.3.3 Expansions
  • 15.1.9 REVVITY, INC.
    • 15.1.9.1 Business overview
    • 15.1.9.2 Products/Services offered
    • 15.1.9.3 Recent developments
      • 15.1.9.3.1 Product/Service launches & approvals
  • 15.1.10 QIAGEN N.V.
    • 15.1.10.1 Business overview
    • 15.1.10.2 Products/Services offered
    • 15.1.10.3 Recent developments
      • 15.1.10.3.1 Product/Service launches & approvals
      • 15.1.10.3.2 Deals
      • 15.1.10.3.3 Expansions
  • 15.1.11 SEEGENE INC.
    • 15.1.11.1 Business overview
    • 15.1.11.2 Products/Services offered
    • 15.1.11.3 Recent developments
      • 15.1.11.3.1 Product/Service launches & approvals
      • 15.1.11.3.2 Deals
      • 15.1.11.3.3 Expansions
• 15.2 OTHER PLAYERS
  • 15.2.1 QUIDELORTHO CORPORATION
  • 15.2.2 GRIFOLS, S.A.
  • 15.2.3 DIASORIN S.P.A
  • 15.2.4 BIO-RAD LABORATORIES, INC.
  • 15.2.5 SYSMEX CORPORATION
  • 15.2.6 ORASURE TECHNOLOGIES, INC.
  • 15.2.7 CO-DIAGNOSTICS, INC.
  • 15.2.8 SD BIOSENSOR, INC.
  • 15.2.9 BIOSYNEX SA
  • 15.2.10 TRINITY BIOTECH
  • 15.2.11 BRUKER (ELITECHGROUP)
  • 15.2.12 GENETIC SIGNATURES
  • 15.2.13 EPITOPE DIAGNOSTICS, INC.
  • 15.2.14 TRIVITRON HEALTHCARE
  • 15.2.15 MERIL LIFE SCIENCES PVT. LTD.
  • 15.2.16 INBIOS INTERNATIONAL, INC.
  • 15.2.17 UNIOGEN OY
  • 15.2.18 VELA DIAGNOSTICS
  • 15.2.19 MOLBIO DIAGNOSTICS LIMITED

16 APPENDIX

• 16.1 DISCUSSION GUIDE
• 16.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 16.3 CUSTOMIZATION OPTIONS
• 16.4 RELATED REPORTS
• 16.5 AUTHOR DETAILS

List of Tables

• TABLE 1 INFECTIOUS DISEASE DIAGNOSTICS MARKET: INCLUSIONS & EXCLUSIONS
• TABLE 2 INFECTIOUS DISEASE DIAGNOSTICS MARKET: KEY DATA FROM PRIMARY SOURCES
• TABLE 3 INFECTIOUS DISEASE DIAGNOSTICS MARKET: RISK ASSESSMENT ANALYSIS
• TABLE 4 REGIONAL HIV DATA, 2024
• TABLE 5 INDICATIVE SELLING PRICING TREND OF INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS, 2023-2025
• TABLE 6 INDICATIVE SELLING PRICE TREND OF INFECTIOUS DISEASE TEST KITS & ASSAYS, BY KEY PLAYER, 2023-2025
• TABLE 7 INDICATIVE SELLING PRICE TREND OF INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS, BY REGION, 2023-2025
• TABLE 8 INFECTIOUS DISEASE DIAGNOSTICS MARKET: LIST OF MAJOR PATENTS
• TABLE 9 IMPORT DATA FOR DIAGNOSTIC & LABORATORY REAGENTS (HS CODE 3822), BY COUNTRY, 2020-2024 (USD MILLION)
• TABLE 10 EXPORT DATA FOR DIAGNOSTIC & LABORATORY REAGENTS (HS CODE 3822), BY COUNTRY, 2020-2024 (USD MILLION)
• TABLE 11 INFECTIOUS DISEASE DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM
• TABLE 12 INFECTIOUS DISEASE DIAGNOSTICS MARKET: PORTER'S FIVE FORCES ANALYSIS
• TABLE 13 CLASSIFICATION OF IVD DEVICES IN EUROPE
• TABLE 14 TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS IN JAPAN
• TABLE 17 ASIA PACIFIC: LIST OF KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 20 INFECTIOUS DISEASE DIAGNOSTICS MARKET: DETAILED LIST OF KEY CONFERENCES & EVENTS, JANUARY 2025-DECEMBER 2026
• TABLE 21 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS (%)
• TABLE 22 KEY BUYING CRITERIA FOR INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS, BY RANK
• TABLE 23 IMPLEMENTATION OF AI, BY KEY COMPANY & CASE
• TABLE 24 US-ADJUSTED RECIPROCAL TARIFF RATES
• TABLE 25 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)T
• TABLE 26 KEY REAGENTS, KITS, AND CONSUMABLES CURRENTLY AVAILABLE
• TABLE 27 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR REAGENTS, KITS, AND CONSUMABLES, BY REGION, 2023-2030 (USD MILLION)
• TABLE 28 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR REAGENTS, KITS, AND CONSUMABLES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 29 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR REAGENTS, KITS, AND CONSUMABLES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 30 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR REAGENTS, KITS, AND CONSUMABLES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 31 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR REAGENTS, KITS, AND CONSUMABLES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 32 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR REAGENTS, KITS, AND CONSUMABLES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 33 KEY INSTRUMENTS CURRENTLY AVAILABLE
• TABLE 34 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 35 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 36 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 37 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 38 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 39 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 40 KEY SOFTWARE & SERVICES CURRENTLY AVAILABLE
• TABLE 41 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY REGION, 2023-2030 (USD MILLION)
• TABLE 42 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 43 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 44 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 45 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 46 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 47 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023-2030 (USD MILLION)
• TABLE 48 KEY LABORATORY TEST TYPES CURRENTLY AVAILABLE
• TABLE 49 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR LABORATORY TESTING, BY REGION, 2023-2030 (USD MILLION)
• TABLE 50 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR LABORATORY TESTING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 51 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR LABORATORY TESTING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 52 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR LABORATORY TESTING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 53 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR LABORATORY TESTING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 54 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR LABORATORY TESTING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 55 KEY POC TESTING TYPES CURRENTLY AVAILABLE
• TABLE 56 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POC TESTING, BY REGION, 2023-2030 (USD MILLION)
• TABLE 57 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POC TESTING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 58 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POC TESTING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 59 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POC TESTING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 60 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POC TESTING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 61 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POC TESTING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 62 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
• TABLE 63 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SAMPLES, BY REGION, 2023-2030 (USD MILLION)
• TABLE 64 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SAMPLES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 65 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SAMPLES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 66 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SAMPLES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 67 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SAMPLES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 68 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR BLOOD, SERUM, AND PLASMA SAMPLES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 69 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR URINE SAMPLES, BY REGION, 2023-2030 (USD MILLION)
• TABLE 70 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 71 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 72 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 73 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 74 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR URINE SAMPLES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 75 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY REGION, 2023-2030 (USD MILLION)
• TABLE 76 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 77 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 78 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 79 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 80 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 81 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023-2030 (USD MILLION)
• TABLE 82 KEY HEPATITIS TESTING PRODUCTS CURRENTLY AVAILABLE
• TABLE 83 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 84 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 85 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 86 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 87 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 88 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 89 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 90 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS B, BY REGION, 2023-2030 (USD MILLION)
• TABLE 91 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS B, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 92 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS B, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 93 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS B, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 94 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS B, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 95 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS B, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 96 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS C, BY REGION, 2023-2030 (USD MILLION)
• TABLE 97 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS C, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 98 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS C, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 99 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS C, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 100 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS C, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 101 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS C, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 102 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER HEPATITIS DISEASES, BY REGION, 2023-2030 (USD MILLION)
• TABLE 103 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER HEPATITIS DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 104 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER HEPATITIS DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 105 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER HEPATITIS DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 106 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER HEPATITIS DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 107 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER HEPATITIS DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 108 KEY HIV TESTING PRODUCTS CURRENTLY AVAILABLE
• TABLE 109 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HIV, BY REGION, 2023-2030 (USD MILLION)
• TABLE 110 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HIV, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 111 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HIV, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 112 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HIV, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 113 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HIV, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 114 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HIV, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 115 KEY HAI TESTING PRODUCTS CURRENTLY AVAILABLE
• TABLE 116 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 117 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 118 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 119 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 120 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 121 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 122 KEY DENGUE-TESTING PRODUCTS CURRENTLY AVAILABLE
• TABLE 123 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR MOSQUITO-BORNE DISEASES, BY REGION, 2023-2030 (USD MILLION)
• TABLE 124 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR MOSQUITO-BORNE DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 125 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR MOSQUITO-BORNE DISEASES, 2023-2030 (USD MILLION)
• TABLE 126 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR MOSQUITO-BORNE DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 127 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR MOSQUITO-BORNE DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 128 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR MOSQUITO-BORNE DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 129 KEY HPV TESTING PRODUCTS CURRENTLY AVAILABLE
• TABLE 130 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HPV, BY REGION, 2023-2030 (USD MILLION)
• TABLE 131 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HPV, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 132 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HPV, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 133 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HPV, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 134 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HPV, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 135 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HPV, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 136 KEY CHLAMYDIA TRACHOMATIS TESTING PRODUCTS CURRENTLY AVAILABLE
• TABLE 137 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 138 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 139 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 140 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 141 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 142 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CHLAMYDIA TRACHOMATIS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 143 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR NEISSERIA GONORRHOEAE, BY REGION, 2023-2030 (USD MILLION)
• TABLE 144 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR NEISSERIA GONORRHOEAE, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 145 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR NEISSERIA GONORRHOEAE, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 146 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR NEISSERIA GONORRHOEAE, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 147 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR NEISSERIA GONORRHOEAE, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 148 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR NEISSERIA GONORRHOEAE, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 149 KEY TUBERCULOSIS TESTING PRODUCTS CURRENTLY AVAILABLE
• TABLE 150 GLOBAL NUMBER OF NEWLY DIAGNOSED TUBERCULOSIS (TB) CASES, 2023-2030 (IN MILLIONS)
• TABLE 151 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 152 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 153 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 154 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 155 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 156 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 157 KEY INFLUENZA TESTING PRODUCTS CURRENTLY AVAILABLE
• TABLE 158 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INFLUENZA, BY REGION, 2023-2030 (USD MILLION)
• TABLE 159 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INFLUENZA, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 160 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INFLUENZA, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 161 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INFLUENZA, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 162 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INFLUENZA, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 163 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR INFLUENZA, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 164 KEY SYPHILIS TESTING PRODUCTS CURRENTLY AVAILABLE
• TABLE 165 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SYPHILIS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 166 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SYPHILIS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 167 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SYPHILIS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 168 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SYPHILIS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 169 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SYPHILIS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 170 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SYPHILIS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 171 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY REGION, 2023-2030 (USD MILLION)
• TABLE 172 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 173 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 174 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 175 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 176 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 177 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 178 KEY IMMUNODIAGNOSTICS-BASED PRODUCTS CURRENTLY AVAILABLE
• TABLE 179 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 180 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 181 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 182 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 183 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 184 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR IMMUNODIAGNOSTICS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 185 KEY CLINICAL MICROBIOLOGY-BASED PRODUCTS CURRENTLY AVAILABLE
• TABLE 186 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CLINICAL MICROBIOLOGY, BY REGION, 2023-2030 (USD MILLION)
• TABLE 187 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CLINICAL MICROBIOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 188 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CLINICAL MICROBIOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 189 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CLINICAL MICROBIOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 190 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CLINICAL MICROBIOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 191 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR CLINICAL MICROBIOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 192 KEY POLYMERASE CHAIN REACTION-BASED PRODUCTS CURRENTLY AVAILABLE
• TABLE 193 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2023-2030 (USD MILLION)
• TABLE 194 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 195 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 196 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 197 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 198 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 199 KEY ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY-BASED PRODUCTS CURRENTLY AVAILABLE
• TABLE 200 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY REGION, 2023-2030 (USD MILLION)
• TABLE 201 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 202 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 203 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 204 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 205 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 206 KEY DNA SEQUENCING & NEXT-GENERATION SEQUENCING-BASED PRODUCTS CURRENTLY AVAILABLE
• TABLE 207 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY REGION, 2023-2030 (USD MILLION)
• TABLE 208 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 209 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, 2023-2030 (USD MILLION)
• TABLE 210 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 211 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 212 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 213 KEY DNA MICROARRAY-BASED PRODUCTS CURRENTLY AVAILABLE
• TABLE 214 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 215 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 216 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 217 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 218 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 219 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 220 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2023-2030 (USD MILLION)
• TABLE 221 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 222 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 223 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 224 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 225 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 226 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)
• TABLE 227 KEY DIAGNOSTICS PRODUCTS CURRENTLY AVAILABLE
• TABLE 228 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTICS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 229 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 230 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 231 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 232 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 233 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTICS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 234 KEY SCREENING PRODUCTS CURRENTLY AVAILABLE
• TABLE 235 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SCREENING, BY REGION, 2023-2030 (USD MILLION)
• TABLE 236 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SCREENING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 237 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SCREENING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 238 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SCREENING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 239 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SCREENING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 240 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR SCREENING, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 241 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 242 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2023-2030 (USD MILLION)
• TABLE 243 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 244 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 245 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 246 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 247 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 248 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 249 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 250 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 251 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 252 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 253 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 254 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY REGION, 2023-2030 (USD MILLION)
• TABLE 255 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 256 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 257 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 258 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 259 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 260 INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2023-2030 (USD MILLION)
• TABLE 261 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 262 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 263 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 264 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 265 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 266 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION, 2023-2030 (USD MILLION)
• TABLE 267 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 268 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 269 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023-2030 (USD MILLION)
• TABLE 270 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
• TABLE 271 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023-2030 (USD MILLION)
• TABLE 272 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 273 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 274 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)
• TABLE 275 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 276 NORTH AMERICA: MACROECONOMIC INDICATORS
• TABLE 277 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 278 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023-2030 (USD MILLION)
• TABLE 279 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
• TABLE 280 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023-2030 (USD MILLION)
• TABLE 281 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 282 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 283 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)
• TABLE 284 US: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 285 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 286 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023-2030 (USD MILLION)
• TABLE 287 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
• TABLE 288 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023-2030 (USD MILLION)
• TABLE 289 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 290 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 291 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)
• TABLE 292 CANADA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 293 EUROPE: MACROECONOMIC INDICATORS
• TABLE 294 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 295 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 296 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023-2030 (USD MILLION)
• TABLE 297 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
• TABLE 298 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023-2030 (USD MILLION)
• TABLE 299 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 300 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 301 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)
• TABLE 302 EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 303 GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 304 GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023-2030 (USD MILLION)
• TABLE 305 GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
• TABLE 306 GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023-2030 (USD MILLION)
• TABLE 307 GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 308 GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 309 GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)
• TABLE 310 GERMANY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 311 UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 312 UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023-2030 (USD MILLION)
• TABLE 313 UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
• TABLE 314 UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023-2030 (USD MILLION)
• TABLE 315 UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 316 UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 317 UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)
• TABLE 318 UK: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 319 FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 320 FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023-2030 (USD MILLION)
• TABLE 321 FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
• TABLE 322 FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023-2030 (USD MILLION)
• TABLE 323 FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 324 FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 325 FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)
• TABLE 326 FRANCE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 327 ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 328 ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023-2030 (USD MILLION)
• TABLE 329 ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
• TABLE 330 ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023-2030 (USD MILLION)
• TABLE 331 ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 332 ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 333 ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)
• TABLE 334 ITALY: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 335 SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 336 SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023-2030 (USD MILLION)
• TABLE 337 SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
• TABLE 338 SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023-2030 (USD MILLION)
• TABLE 339 SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 340 SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 341 SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)
• TABLE 342 SPAIN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 343 GDP EXPENDITURE ON HEALTHCARE, BY COUNTRY (%)
• TABLE 344 REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 345 REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023-2030 (USD MILLION)
• TABLE 346 REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
• TABLE 347 REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023-2030 (USD MILLION)
• TABLE 348 REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 349 REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 350 REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)
• TABLE 351 REST OF EUROPE: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 352 ASIA PACIFIC: MACROECONOMIC INDICATORS
• TABLE 353 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 354 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 355 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023-2030 (USD MILLION)
• TABLE 356 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
• TABLE 357 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023-2030 (USD MILLION)
• TABLE 358 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 359 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 360 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)
• TABLE 361 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 362 CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 363 CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023-2030 (USD MILLION)
• TABLE 364 CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
• TABLE 365 CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023-2030 (USD MILLION)
• TABLE 366 CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 367 CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 368 CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)
• TABLE 369 CHINA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 370 JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 371 JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023-2030 (USD MILLION)
• TABLE 372 JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
• TABLE 373 JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023-2030 (USD MILLION)
• TABLE 374 JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 375 JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 376 JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)
• TABLE 377 JAPAN: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 378 INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 379 INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023-2030 (USD MILLION)
• TABLE 380 INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
• TABLE 381 INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023-2030 (USD MILLION)
• TABLE 382 INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 383 INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 384 INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)
• TABLE 385 INDIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 386 REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 387 REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023-2030 (USD MILLION)
• TABLE 388 REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
• TABLE 389 REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023-2030 (USD MILLION)
• TABLE 390 REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 391 REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 392 REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)
• TABLE 393 REST OF ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 394 LATIN AMERICA: MACROECONOMIC INDICATORS
• TABLE 395 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 396 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 397 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023-2030 (USD MILLION)
• TABLE 398 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
• TABLE 399 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023-2030 (USD MILLION)
• TABLE 400 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 401 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 402 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)
• TABLE 403 LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 404 BRAZIL: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 405 BRAZIL: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023-2030 (USD MILLION)
• TABLE 406 BRAZIL: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
• TABLE 407 BRAZIL: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023-2030 (USD MILLION)
• TABLE 408 BRAZIL: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 409 BRAZIL: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 410 BRAZIL: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)
• TABLE 411 BRAZIL: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 412 MEXICO: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 413 MEXICO: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023-2030 (USD MILLION)
• TABLE 414 MEXICO: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
• TABLE 415 MEXICO: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023-2030 (USD MILLION)
• TABLE 416 MEXICO: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 417 MEXICO: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 418 MEXICO: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)
• TABLE 419 MEXICO: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 420 REST OF LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 421 REST OF LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023-2030 (USD MILLION)
• TABLE 422 REST OF LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
• TABLE 423 REST OF LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023-2030 (USD MILLION)
• TABLE 424 REST OF LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 425 REST OF LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 426 REST OF LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)
• TABLE 427 REST OF LATIN AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 428 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS
• TABLE 429 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
• TABLE 430 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 431 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023-2030 (USD MILLION)
• TABLE 432 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
• TABLE 433 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023-2030 (USD MILLION)
• TABLE 434 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 435 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 436 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)
• TABLE 437 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 438 KINGDOM OF SAUDI ARABIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 439 KINGDOM OF SAUDI ARABIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023-2030 (USD MILLION)
• TABLE 440 KINGDOM OF SAUDI ARABIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
• TABLE 441 KINGDOM OF SAUDI ARABIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023-2030 (USD MILLION)
• TABLE 442 KINGDOM OF SAUDI ARABIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 443 KINGDOM OF SAUDI ARABIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 444 KINGDOM OF SAUDI ARABIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)
• TABLE 445 KINGDOM OF SAUDI ARABIA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 446 UNITED ARAB EMIRATES: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 447 UNITED ARAB EMIRATES: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023-2030 (USD MILLION)
• TABLE 448 UNITED ARAB EMIRATES: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
• TABLE 449 UNITED ARAB EMIRATES: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023-2030 (USD MILLION)
• TABLE 450 UNITED ARAB EMIRATES: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 451 UNITED ARAB EMIRATES: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 452 UNITED ARAB EMIRATES: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)
• TABLE 453 UNITED ARAB EMIRATES: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 454 REST OF MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2023-2030 (USD MILLION)
• TABLE 455 REST OF MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2023-2030 (USD MILLION)
• TABLE 456 REST OF MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2023-2030 (USD MILLION)
• TABLE 457 REST OF MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2023-2030 (USD MILLION)
• TABLE 458 REST OF MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET FOR HEPATITIS, BY TYPE, 2023-2030 (USD MILLION)
• TABLE 459 REST OF MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
• TABLE 460 REST OF MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2023-2030 (USD MILLION)
• TABLE 461 REST OF MIDDLE EAST & AFRICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2023-2030 (USD MILLION)
• TABLE 462 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES IN THE INFECTIOUS DISEASE DIAGNOSTICS MARKET, JANUARY 2021-JUNE 2025
• TABLE 463 INFECTIOUS DISEASE DIAGNOSTICS MARKET: DEGREE OF COMPETITION
• TABLE 464 INFECTIOUS DISEASE DIAGNOSTICS MARKET: REGION FOOTPRINT
• TABLE 465 INFECTIOUS DISEASE DIAGNOSTICS MARKET: PRODUCT & SERVICE FOOTPRINT
• TABLE 466 INFECTIOUS DISEASE DIAGNOSTICS MARKET: TYPE OF TESTING FOOTPRINT
• TABLE 467 INFECTIOUS DISEASE DIAGNOSTICS MARKET: SAMPLE TYPE FOOTPRINT
• TABLE 468 INFECTIOUS DISEASE DIAGNOSTICS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
• TABLE 469 INFECTIOUS DISEASE DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (1/2)
• TABLE 470 INFECTIOUS DISEASE DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (2/2)
• TABLE 471 INFECTIOUS DISEASE DIAGNOSTICS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-JUNE 2025
• TABLE 472 INFECTIOUS DISEASE DIAGNOSTICS MARKET: DEALS, JANUARY 2021-JUNE 2025
• TABLE 473 INFECTIOUS DISEASE DIAGNOSTICS MARKET: EXPANSIONS, JANUARY 2021- JUNE 2025
• TABLE 474 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
• TABLE 475 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES OFFERED
• TABLE 476 F. HOFFMANN-LA ROCHE LTD.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021-JUNE 2025
• TABLE 477 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2021-JUNE 2025
• TABLE 478 F. HOFFMANN-LA ROCHE LTD.: EXPANSIONS, JANUARY 2021-JUNE 2025
• TABLE 479 ABBOTT: COMPANY OVERVIEW
• TABLE 480 ABBOTT: PRODUCTS/SERVICES OFFERED
• TABLE 481 ABBOTT: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021-JUNE 2025
• TABLE 482 ABBOTT: DEALS, JANUARY 2021-JUNE 2025
• TABLE 483 DANAHER CORPORATION: COMPANY OVERVIEW
• TABLE 484 DANAHER CORPORATION: PRODUCTS/SERVICES OFFERED
• TABLE 485 DANAHER CORPORATION: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021-JUNE 2025
• TABLE 486 DANAHER CORPORATION: DEALS, JANUARY 2021-JUNE 2025
• TABLE 487 DANAHER CORPORATION: EXPANSIONS, JANUARY 2021-JUNE 2025
• TABLE 488 BIOMERIEUX: COMPANY OVERVIEW
• TABLE 489 BIOMERIEUX: PRODUCTS/SERVICES OFFERED
• TABLE 490 BIOMERIEUX: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021-JUNE 2025
• TABLE 491 BIOMERIEUX: DEALS, JANUARY 2021- JUNE 2025
• TABLE 492 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
• TABLE 493 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES OFFERED
• TABLE 494 THERMO FISHER SCIENTIFIC INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021-JUNE 2025
• TABLE 495 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021-JUNE 2025
• TABLE 496 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
• TABLE 497 SIEMENS HEALTHINEERS AG: PRODUCTS/SERVICES OFFERED
• TABLE 498 SIEMENS HEALTHINEERS AG: PRODUCT LAUNCHES, JANUARY 2021-JUNE 2025
• TABLE 499 SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2021-JUNE 2025
• TABLE 500 SIEMENS HEALTHINEERS AG: EXPANSIONS, JANUARY 2021-JUNE 2025
• TABLE 501 HOLOGIC, INC.: COMPANY OVERVIEW
• TABLE 502 HOLOGIC, INC.: PRODUCTS/SERVICES OFFERED
• TABLE 503 HOLOGIC, INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021-JUNE 2025
• TABLE 504 HOLOGIC, INC.: DEALS, JANUARY 2021- JUNE 2025
• TABLE 505 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW
• TABLE 506 BECTON, DICKINSON AND COMPANY: PRODUCTS/SERVICES OFFERED
• TABLE 507 BECTON, DICKINSON AND COMPANY: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021-JUNE 2025
• TABLE 508 BD: DEALS, JANUARY 2021-JUNE 2025
• TABLE 509 BD: EXPANSIONS, JANUARY 2021- JUNE 2025
• TABLE 510 REVVITY, INC.: COMPANY OVERVIEW
• TABLE 511 REVVITY, INC.: PRODUCTS/SERVICES OFFERED
• TABLE 512 REVVITY INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021-JUNE 2025
• TABLE 513 QIAGEN N.V.: COMPANY OVERVIEW
• TABLE 514 QIAGEN N.V.: PRODUCTS/SERVICES OFFERED
• TABLE 515 QIAGEN N.V.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021-JUNE 2025
• TABLE 516 QIAGEN N.V.: DEALS, JANUARY 2021-JUNE 2025
• TABLE 517 QIAGEN N.V.: EXPANSIONS, JANUARY 2021-JUNE 2025
• TABLE 518 SEEGENE INC.: COMPANY OVERVIEW
• TABLE 519 SEEGENE INC.: PRODUCTS/SERVICES OFFERED
• TABLE 520 SEEGENE INC.: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2021-JUNE 2025
• TABLE 521 SEEGENE INC.: DEALS, JANUARY 2021- JUNE 2025
• TABLE 522 SEEGENE INC.: EXPANSIONS, JANUARY 2021- JUNE 2025
• TABLE 523 QUIDELORTHO CORPORATION: COMPANY OVERVIEW
• TABLE 524 GRIFOLS, S.A.: COMPANY OVERVIEW
• TABLE 525 DIASORIN S.P.A.: COMPANY OVERVIEW
• TABLE 526 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
• TABLE 527 SYSMEX CORPORATION: COMPANY OVERVIEW
• TABLE 528 ORASURE TECHNOLOGIES, INC.: COMPANY OVERVIEW
• TABLE 529 CO-DIAGNOSTICS, INC.: COMPANY OVERVIEW
• TABLE 530 SD BIOSENSOR, INC.: COMPANY OVERVIEW
• TABLE 531 BIOSYNEX SA: COMPANY OVERVIEW
• TABLE 532 TRINITY BIOTECH: COMPANY OVERVIEW
• TABLE 533 BRUKER (ELITECHGROUP): COMPANY OVERVIEW
• TABLE 534 GENETIC SIGNATURES: COMPANY OVERVIEW
• TABLE 535 EPITOPE DIAGNOSTICS, INC.: COMPANY OVERVIEW
• TABLE 536 TRIVITRON HEALTHCARE: COMPANY OVERVIEW
• TABLE 537 MERIL LIFE SCIENCES PVT. LTD.: COMPANY OVERVIEW
• TABLE 538 INBIOS INTERNATIONAL, INC.: COMPANY OVERVIEW
• TABLE 539 UNIOGEN OY: COMPANY OVERVIEW
• TABLE 540 VELA DIAGNOSTICS: COMPANY OVERVIEW
• TABLE 541 MOLBIO DIAGNOSTICS LIMITED: COMPANY OVERVIEW

List of Figures

• FIGURE 1 INFECTIOUS DISEASE DIAGNOSTICS MARKET SEGMENTATION & REGIONAL SCOPE
• FIGURE 2 INFECTIOUS DISEASE DIAGNOSTICS MARKET: RESEARCH DESIGN METHODOLOGY
• FIGURE 3 PRIMARY SOURCES
• FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
• FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
• FIGURE 6 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
• FIGURE 7 CAGR PROJECTIONS: SUPPLY SIDE ANALYSIS T
• FIGURE 8 INFECTIOUS DISEASE DIAGNOSTICS MARKET: TOP-DOWN APPROACH
• FIGURE 9 DATA TRIANGULATION METHODOLOGY
• FIGURE 10 INFECTIOUS DISEASE DIAGNOSTICS MARKET: RESEARCH ASSUMPTIONS
• FIGURE 11 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2025 VS. 2030 (USD MILLION)
• FIGURE 12 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TYPE OF TESTING, 2025 VS. 2030 (USD MILLION)
• FIGURE 13 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2025 VS. 2030 (USD MILLION)
• FIGURE 14 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2025 VS. 2030 (USD MILLION)
• FIGURE 15 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY DISEASE TYPE, 2025 VS. 2030 (USD MILLION)
• FIGURE 16 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY CLINICAL APPLICATION, 2025 VS. 2030 (USD MILLION)
• FIGURE 17 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
• FIGURE 18 INFECTIOUS DISEASE DIAGNOSTICS MARKET, BY REGION, 2025 VS. 2030 (USD MILLION)
• FIGURE 19 RISING FOCUS ON R&D FOR INFECTIOUS DISEASE DIAGNOSTICS TO PROPEL MARKET
• FIGURE 20 REAGENTS, KITS, AND CONSUMABLES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
• FIGURE 21 LABORATORY TESTING SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
• FIGURE 22 BLOOD, SERUM, AND PLASMA SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
• FIGURE 23 HEPATITIS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
• FIGURE 24 IMMUNODIAGNOSTICS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
• FIGURE 25 DIAGNOSTICS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
• FIGURE 26 DIAGNOSTIC LABORATORIES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
• FIGURE 27 ASIA PACIFIC REGION TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
• FIGURE 28 INFECTIOUS DISEASE DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
• FIGURE 29 PATENT ANALYSIS FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGIES (JANUARY 2015-DECEMBER 2024)
• FIGURE 30 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING & ASSEMBLY PHASES
• FIGURE 31 INFECTIOUS DISEASE DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS
• FIGURE 32 INFECTIOUS DISEASE DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS
• FIGURE 33 INFECTIOUS DISEASE DIAGNOSTICS MARKET: PORTER'S FIVE FORCES ANALYSIS
• FIGURE 34 INFECTIOUS DISEASE DIAGNOSTICS MARKET: TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• FIGURE 35 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS
• FIGURE 36 KEY BUYING CRITERIA FOR INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS
• FIGURE 37 NUMBER OF DEALS & FUNDING ACTIVITIES IN INFECTIOUS DISEASE DIAGNOSTICS MARKET
• FIGURE 38 MARKET POTENTIAL OF AI IN INFECTIOUS DISEASE DIAGNOSTICS MARKET
• FIGURE 39 NORTH AMERICA: INFECTIOUS DISEASE DIAGNOSTICS MARKET SNAPSHOT
• FIGURE 40 ASIA PACIFIC: INFECTIOUS DISEASE DIAGNOSTICS MARKET SNAPSHOT
• FIGURE 41 REVENUE ANALYSIS OF KEY PLAYERS IN INFECTIOUS DISEASE DIAGNOSTICS MARKET (2022-2024)
• FIGURE 42 MARKET SHARE ANALYSIS OF KEY PLAYERS IN INFECTIOUS DISEASE DIAGNOSTICS MARKET (2024)
• FIGURE 43 INFECTIOUS DISEASE DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
• FIGURE 44 INFECTIOUS DISEASE DIAGNOSTICS MARKET: COMPANY FOOTPRINT
• FIGURE 45 INFECTIOUS DISEASE DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
• FIGURE 46 EV/EBITDA OF KEY VENDORS
• FIGURE 47 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
• FIGURE 48 INFECTIOUS DISEASE DIAGNOSTICS MARKET: BRAND COMPARISON FOR INSTRUMENTS
• FIGURE 49 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2024)
• FIGURE 50 ABBOTT: COMPANY SNAPSHOT (2024)
• FIGURE 51 DANAHER CORPORATION: COMPANY SNAPSHOT (2024)
• FIGURE 52 BIOMERIEUX: COMPANY SNAPSHOT (2024)
• FIGURE 53 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024)
• FIGURE 54 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2024)
• FIGURE 55 HOLOGIC, INC.: COMPANY SNAPSHOT (2024)
• FIGURE 56 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2024)
• FIGURE 57 REVVITY, INC.: COMPANY SNAPSHOT (2024)
• FIGURE 58 QIAGEN N.V.: COMPANY SNAPSHOT (2024)
• FIGURE 59 SEEGENE INC.: COMPANY SNAPSHOT (2024)